Andrea Apolo, M.D. (@apolo_andrea) 's Twitter Profile
Andrea Apolo, M.D.

@apolo_andrea

Medical Oncologist, Senior Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina Views are my own

ID: 2419804603

calendar_today31-03-2014 01:47:20

10,10K Tweet

7,7K Followers

2,2K Following

Shilpa Gupta (@shilpaonc) 's Twitter Profile Photo

What an amazing #BCANTT24 it was! Thx Eugene Pietzak Stephanie Chisolm, PhD Rebecca Johnson, SC members, co-chairs, speakers, pt advocates & attendees for a fantastic meeting. It was all about patients from beginning to end! Looking forward to working w/ Max Kates for planning #BCANTT25

What an amazing #BCANTT24 it was! Thx <a href="/eugene_pietzak/">Eugene Pietzak</a> <a href="/bcan_chisolm/">Stephanie Chisolm, PhD</a> <a href="/BCAN_Research/">Rebecca Johnson</a>, SC members, co-chairs, speakers, pt advocates &amp; attendees for a fantastic meeting. It was all about patients from beginning to end! Looking forward to working w/ <a href="/MaxKates/">Max Kates</a> for planning #BCANTT25
Pavlos Msaouel (@pavlosmsaouel) 's Twitter Profile Photo

The second #MsaouelLab R01 proposal has now been funded to investigate #RenalMedullaryCarcinoma as a model to understand and target key cancer hallmarks. This one is a multiPI collaborative effort with each team synergizing to identify unifying principles. #kidneycancer #endRMC

The second #MsaouelLab R01 proposal has now been funded to investigate #RenalMedullaryCarcinoma as a model to understand and target key cancer hallmarks. This one is a multiPI collaborative effort with each team synergizing to identify unifying principles. #kidneycancer #endRMC
Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship. I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship.  I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7
Philippe spiess (@spiessphilippe) 's Twitter Profile Photo

Very sorry to hear of Jeff’s passing. He was the true model of the successful clinical scientist. RIP Jeff and thanks for your invaluable contributions. It was a pleasure working with you in my early day’s at Moffitt 💙🙏🏻

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

1/ Results from #LITESPARK-005 are out <a href="/NEJM/">NEJM</a>! 
The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) <a href="/US_FDA/">U.S. FDA</a> approval Dec 2023 in pretreated pts w/ #ccRCC. 
Presentation #ESMO24 @myEsmo

Check it out: nejm.org/doi/full/10.10…
Tom Powles (@tompowles1) 's Twitter Profile Photo

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

TROPHY-U-01 Cohort 2: Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). #cancer #oncology OncoAlert Scott Tagawa Cora Sternberg

TROPHY-U-01 Cohort 2: 
Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). 
#cancer #oncology <a href="/OncoAlert/">OncoAlert</a> 
<a href="/DrScottTagawa/">Scott Tagawa</a> <a href="/cnsternberg/">Cora Sternberg</a>
Andrea Apolo, M.D. (@apolo_andrea) 's Twitter Profile Photo

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer ⁦Nicholas Simon⁩ link.springer.com/article/10.100…

Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Just in <a href="/Annals_Oncology/">Annals of Oncology</a> 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 <a href="/urotoday/">UroToday.com</a> <a href="/OncoAlert/">OncoAlert</a>  <a href="/kidneycan/">KidneyCAN</a> <a href="/huntsmancancer/">Huntsman Cancer Institute</a>
OncoAlert (@oncoalert) 's Twitter Profile Photo

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

Dear Colleagues,
The <a href="/OncoAlert/">OncoAlert</a> 🚨Network Presents OUR Picks of  TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24

This List Curated by:
#OncoAlertAF Leads
<a href="/HHorinouchi/">Hidehito HORINOUCHI</a> 🇯🇵
<a href="/BiagioRicciutMD/">Biagio Ricciuti, MD PhD</a> 🇺🇸
<a href="/lungoncdoc/">Eric K. Singhi, MD</a> 🇺🇸
<a href="/weoncologists/">Gil Morgan, MD</a> 🇺🇸

With our Distinguished <a href="/OncoAlert/">OncoAlert</a> 🚨Faculty
Tom Powles (@tompowles1) 's Twitter Profile Photo

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important  than predefined  criteria <a href="/apolo_andrea/">Andrea Apolo, M.D.</a> <a href="/shilpaonc/">Shilpa Gupta</a> <a href="/OncoBellmunt/">joaquim bellmunt</a> <a href="/DrRosenbergMSK/">Jonathan Rosenberg MD</a> <a href="/MichvdHeijden/">Michiel van der Heijden</a> &amp; Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC! - #NIAGARA - #KN522 - #NATALEE - #DB12 - #MARIPOSA2 - #KRYSTAL12 - #NICHE2 - #SAKK41 - #POD1UM - #KN811 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ESMO - Eur. Oncology OncoAlert

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC!

- #NIAGARA
- #KN522
- #NATALEE
- #DB12
- #MARIPOSA2
- #KRYSTAL12
- #NICHE2
- #SAKK41 
- #POD1UM 
- #KN811  

#BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/OncoAlert/">OncoAlert</a>
soria (@jsoriamd) 's Twitter Profile Photo

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…

Frequency of HER2 alterations across tumor types &amp; current development landscape of HER2-targeted therapies summarized in this publication. 
nature.com/articles/s4157…